Benzinga | Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals

Skip to main content

Market Overview

0.0000 0 (%)

Data as of Dec 25, 2024

Prev. Close
Price Open
Volume 0
Day's Range -
52 Wk Range -
50 Day Moving Avg.
PE Ratio
Shares Outstanding
Market Cap

Trade RLYP stock for free with recommended broker TD Ameritrade.

Analyst Rating View All Ratings

The 7 Biggest Market Rumors Of 2016: Where Are They Now? Wayne DugganWed, 21 Dec 2016 15:25:19 -0500
Galenica Completes Acquisition of Relypsa Charles GrossFri, 02 Sep 2016 03:29:46 -0500
Relypsa Phase 4 Veltassa Trial Met Primary Endpoint Paul QuintaroTue, 30 Aug 2016 15:05:56 -0500
Watch These 7 Huge Call Purchases In Wednesday Trade Monica GersonWed, 24 Aug 2016 01:06:27 -0500
Option Alert: RLYP Sep16 32.0 Calls Sweep: 550 @ ASK $0.10: 560 traded vs 106k OI: $31.99 Ref Charles GrossTue, 23 Aug 2016 11:14:22 -0500
Benzinga's Top Downgrades Monica GersonMon, 22 Aug 2016 08:49:13 -0500
The Market In 5 Minutes: Indexes Remain In Tight Range As Rio Olympics Come To An End Benzinga News DeskMon, 22 Aug 2016 08:03:43 -0500
Stifel Nicolaus Downgrades Relypsa to Hold Paul QuintaroMon, 22 Aug 2016 05:25:42 -0500
Oppenheimer Terminates Outperform Rating on Relypsa Paul QuintaroTue, 09 Aug 2016 06:38:49 -0500
The Market In 5 Minutes: Bank Of England Cut Interest Rates For The First Time In 7 Years Benzinga News DeskThu, 04 Aug 2016 07:59:24 -0500
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Covered Call Alerts For Disney, Juno Therapeutics Inc, Relypsa, Bojangles Inc. and Terraform Power Released By InvestorsObserver PRNewswireSep 17, 2016
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies Globe NewswireSep 02, 2016
Galenica completes acquisition of Relypsa, strengthening Vifor Pharma's position in cardio-renal therapies Thomson ReutersSep 02, 2016
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa Globe NewswireSep 01, 2016
Galenica announces Expiration of Cash Tender Offer for Shares of Common Stock of Relypsa Thomson ReutersSep 01, 2016
Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia Globe NewswireAug 30, 2016
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Relypsa, Inc. (RLYP) Globe NewswireAug 15, 2016
Galenica commences Tender Offer for Relypsa Globe NewswireAug 04, 2016
Galenica commences Tender Offer for Relypsa Thomson ReutersAug 04, 2016
RELYPSA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Relypsa, Inc. (RLYP) Over the Proposed Sale of the Company to Galenica Group PRNewswireJul 25, 2016
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

FDA OKs label update for Relypsa's Veltassa Seeking AlphaMay 08, 2018
Biotech Forum Daily Digest: Biotech Closes Above Resistance Levels. Icahn Getting Interested In Sector? Seeking AlphaMar 06, 2017
ACADIA Pharma Looks Like A Take-Out Target Seeking AlphaFeb 27, 2017
Biotech Forum Daily Digest: Can Aerie Pharmaceuticals Continue To Rally? Spotlight On OncoMed Pharmaceuticals Seeking AlphaFeb 26, 2017
Ardelyx launches two studies evaluating RDX7675 in patients with excess blood potassium Seeking AlphaJan 03, 2017
The Vetr community has downgraded $RLYP to 3.5-Stars VetrDec 28, 2016
The 7 Biggest Market Rumors Of 2016: Where Are They Now? Wayne DugganDec 21, 2016
Global Blood Therapeutics: Short-Sellers Could Be In For A Ride Seeking AlphaDec 07, 2016
Biotech Forum Daily Digest: Follow Up On Progenics, Dynavax's Roller Coaster Week, Spotlight On SCYNEXIS Seeking AlphaOct 05, 2016
Marketplace Roundtable: The State Of Biotech Seeking AlphaOct 01, 2016
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q2 2016	EST	Actual	Surprise
EPS:	-1.56	-1.87	-0.3100
Rev:	5.45M	5.22M	-229.00K

	EST	Actual	Surprise
EPS:	Expected
Rev:	Expected